Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
KONOPLEVA, MARINA
One or more keywords matched the following items that are connected to KONOPLEVA, MARINA
Item TypeName
Academic Article MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Concept MAP Kinase Kinase 2
Concept Mitogen-Activated Protein Kinase Kinases
Concept MAP Kinase Kinase Kinases
Concept MAP Kinase Kinase 4
Concept MAP Kinase Kinase 1
Academic Article Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.
Academic Article MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Academic Article Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
Academic Article Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Academic Article Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
Academic Article Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
Academic Article Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
Academic Article Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Academic Article PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Academic Article Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
Academic Article A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Search Criteria
  • Mitogen Activated Protein Kinase Kinases